**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 65-year-old man developed a paradoxical immunologic response to nivolumab in the form of COVID-19, following treatment for advanced lung cancer.

The man presented to hospital on 4 March 2020, with fever, shortness of breath and mental confusion. Haemogasanalysis revealed hypoxia, whereas laboratory tests showed normal leucocytes with lymphopenia, with elevated CRP, LDH and transaminase levels. Chest X-ray revealed reticular interstitial addensative findings, and a nasal swab was found to be positive for COVID-19. Of note, his medical history was significant for lung adenocarcinoma diagnosed in August 2012 and emphysema. He had subsequently undergone cerebral metastasectomy, followed by panencephalic radiotherapy and chemotherapy with pemetrexed and carboplatin, until July 2013. Eventually, disease progression had became evident; hence he was subsequently enrolled into a clinical trial (CA209-057), wherein he had started received nivolumab \[*route and dosage not stated*\] from August 2013 to 14 February 2020. On 5 March 2020, he was hospitalised due to the aforementioned symptoms.

As per the WHO\'s guidelines for the management of COVID-19, the man was treated with empiric antimicrobial therapy, oxygen and other symptomatic treatment \[*specific drugs not stated*\]. He was sedated due to agitation; hence, he did not receive the prescribed hydroxychloroquine and lopinavir plus ritonavir. He exhibited rapid worsening of his condition and passed away on 9 March 2020. It was believed that his history of long exposure to immunotherapy with nivolumab predisposed him to a paradoxical immunologic response in the form of COVID-19.
